"Unequal Hope: Assessing the Cost and Effectiveness of New Alzheimer's Treatments"

New Alzheimer’s drugs like Leqembi and donanemab offer hope for patients, but there is concern about the lack of data on how these medications might work in people of color, particularly African Americans. Low enrollment of Black patients in clinical trials raises questions about the drugs' effectiveness and safety for this population. Experts emphasize the need for more diversity in trials and urge the development of treatments targeting multiple potential drivers of cognitive decline to address disparities in Alzheimer’s treatment and care.